Opinion: Rethinking Scientific Evaluation

Asymmetry in the Research Excellence Framework in the U.K. is a threat to basic medical sciences within British medical schools.

Written byRichard Naftalin
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The quad of King's College Medical School Guys Campus RICHARD NAFTALINThe upcoming Research Excellence Framework (REF) facing British universities in 2014 is a major threat to physiology and other basic medical sciences. The primary focus of REF will be to assess research excellence of tenured university professors, as demonstrated by the quality of their research publications. This new system for assessing the quality of research in UK higher education will be undertaken by the country’s four major funding bodies and will be used from 2015–2016 to selectively allocate research funding.

Basic medical sciences and clinical science departments within the medical schools are in direct competition for financial and human resources and will be judged by the same panel of experts and the same criteria. To be included as an active research scientist in an elite university’s submission to REF requires three recently published papers in journals with high impact factors. The number of citations that each submitted paper attracts will also count but in elite institutions only papers published in journals with an impact factor of 5 or greater will be submitted for assessment by REF. Papers graded by REF as “outstanding” will earn their institution £100,000 (~$154,000); those rated merely “excellent” will be awarded £25,000 (~$38,500); anything less will be given no funding.

Three ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies